Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis

Table 2 Baseline characteristics after propensity score-overlap weighting

Variable	Andexanet alfa n = 107	4F-PCC n = 95
Demographics
Age (years), mean ± SD	79 ± 8	79 ± 11
Male, %	49.6	49.6
Body mass index (kg/m²), mean ± SD	28 ± 7	28 ± 6
Creatinine clearance (mL/min), mean ± SD	67 ± 30	67 ± 39
Systolic blood pressure > 160 mm Hg, %^a	18.3	18.3
GCS score, %^b	14 ± 1	14 ± 2
Anticoagulant indication and medical history, %
Anticoagulant indication, atrial fibrillation	86.4	86.4
Medical history of heart failure	22.3	22.3
Medical history of diabetes	28.7	28.7
Medical history of myocardial infarction	9.4	9.4
Medical history of stroke	24.0	24.0
Concomitant use of an antiplatelet	24.2	24.2
Intracranial hemorrhage characteristics
Initial imaging to reversal start (hours), mean ± SD	2.3 ± 1.6	2.3 ± 2.1
End of reversal to repeat imaging (hours), mean ± SD	12.2 ± 1.1	12.2 ± 4.6
Traumatic onset, %	61.1	61.1
Infratentorial location, %	14.7	14.7
Size of bleed ≥ 10 mL/mm, %	21.7	21.7
Single compartment bleed, %	78.3	78.3
Intracerebral and/or intraventricular bleed, %^c	53.3	53.3
Subdural bleed, %^c	38.4	38.4
Subarachnoid bleed, %^c	34.3	34.3
Reversal agent dosing, %^b
Andexanet alfa
400 mg bolus + 440 mg infusion	96.6	–
800 mg bolus + 860 mg infusion	3.4	–
4F-PCC
25 units/kg infusion	–	79.3
50 units/kg infusion	–	20.7

4F-PCC = four-factor prothrombin complex concentrate, GCS = Glasgow Coma Scale, SD = standard deviation
^aBlood pressure reported was an average of measurements upon arrival and immediately prior to reversal agent administration
^bNot included in the propensity score model
^cIntracranial hemorrhage types add up to > 100% given a portion of patients had multicompartment bleeds

ISSN: 1364-8535